{
    "SPADE_UN_18957": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_18957",
            "Peptide Name": "Mastoparan-MO (Masto-MO, Mastoparan-L analog, Synthetic AMPs, Leu-rich, XXA, UCLL1c)",
            "Source": "Designed, motif FLPII + natural AMP",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "FLPIIINLKALAALAKKIL",
            "Sequence Length": 19,
            "UniProt Entry": "",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Antiviral"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 2063.65,
            "PI": 10.3,
            "Hydrophobicity": 1.59,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Silva ON, Torres MDT, Cao J, Alves ESF, Rodrigues LV, Resende JM, LiÃ£o LM, Porto WF, Fensterseifer ICM, Lu TK, Franco OL, de la Fuente-Nunez C. 2020",
                    "Reference": "Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26936-26945. doi: 10.1073/pnas.2012379117.PubMed",
                    "Title": "Repurposing a peptide toxin from wasp venom into antiinfectives with dual antimicrobial and immunomodulatory properties."
                }
            ],
            "Frequent Amino Acids": "LAI",
            "Absent Amino Acids": "CDEGHMOQRSTUVWY",
            "Basic Residues": 3,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 15,
            "Polar Residues": 8,
            "Positive Residues": 3,
            "Negative Residues": 0,
            "Net Charge": 3,
            "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (73.68%) toMastoparan-LL: 26%, I=A: 21%, K: 16%.Activity: Active against B. subtilis (to be completed). Inhibited entry of Human alphaherpesvirus 1 (HSV-1) (EC50 6.68 uM).In vitro toxicity: LC100: concentration at which cells were completely killed. Human RBC (LC100 400 uM),   murine fibroblasts L929 (LC100 >400 uM), murine macrophages monocytes RAW 264.7 (LC100 >400 uM), and human embryonic kidney HEK293 cells (LC100 25 uM).Structure:  random coil in water or POPC and helical in 50% TFE, 100 mM SDS, POPG.You can rotate, zoom, and view the NMR structureherein the PDB.In vivo toxicity:mice: no observed toxic effect till 50 mg/kg when IP injected.Animal model:mouse: To be completed.",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_05710",
                    "Similarity": 1.0,
                    "Sequence": "INLKALAALAKKIL"
                },
                {
                    "SPADE_ID": "SPADE_UN_16236",
                    "Similarity": 1.0,
                    "Sequence": "INLKALAALAKKIL"
                },
                {
                    "SPADE_ID": "SPADE_UN_18965",
                    "Similarity": 1.0,
                    "Sequence": "INLKALAALAKKILYSPWTNF"
                }
            ]
        }
    }
}